First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study

Background: Aminopeptidase N (CD13) is present on tumor vasculature cells and some tumor cells. Truncated tissue factor (tTF) with a C-terminal NGR-peptide (tTF-NGR) binds to CD13 and causes tumor vascular thrombosis with infarction. Methods: We treated 17 patients with advanced cancer beyond standa...

Descripción completa

Detalles Bibliográficos
Autores principales: Schliemann, Christoph, Gerwing, Mirjam, Heinzow, Hauke, Harrach, Saliha, Schwöppe, Christian, Wildgruber, Moritz, Hansmeier, Anna A., Angenendt, Linus, Berdel, Andrew F., Stalmann, Ursula, Berning, Björna, Kratz-Albers, Karsten, Middelberg-Bisping, Kristina, Wiebe, Stefanie, Albring, Jörn, Wilms, Christian, Hartmann, Wolfgang, Wardelmann, Eva, Krähling, Tobias, Heindel, Walter, Gerss, Joachim, Bormann, Eike, Schmidt, Hartmut, Lenz, Georg, Kessler, Torsten, Mesters, Rolf M., Berdel, Wolfgang E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352358/
https://www.ncbi.nlm.nih.gov/pubmed/32517329
http://dx.doi.org/10.3390/cancers12061488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352358/
https://www.ncbi.nlm.nih.gov/pubmed/32517329
http://dx.doi.org/10.3390/cancers12061488

Ejemplares similares